ABIOMED, Inc. (NASDAQ:ABMD) has been assigned a consensus recommendation of “Buy” from the ten brokerages that are covering the firm, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $157.50.

A number of equities research analysts recently issued reports on ABMD shares. Morgan Stanley reissued an “equal weight” rating and issued a $140.00 price target (up previously from $135.00) on shares of ABIOMED in a research note on Monday, July 10th. William Blair reissued an “outperform” rating on shares of ABIOMED in a research note on Thursday, June 8th. Zacks Investment Research cut shares of ABIOMED from a “buy” rating to a “hold” rating in a research note on Wednesday, July 5th. Piper Jaffray Companies set a $145.00 price target on shares of ABIOMED in a research note on Tuesday, July 4th. Finally, Jefferies Group LLC lifted their price target on shares of ABIOMED from $165.00 to $175.00 and gave the company a “buy” rating in a research note on Friday, August 4th.

In other ABIOMED news, COO David M. Weber sold 16,500 shares of the firm’s stock in a transaction on Monday, July 31st. The stock was sold at an average price of $147.63, for a total value of $2,435,895.00. Following the transaction, the chief operating officer now owns 125,122 shares in the company, valued at approximately $18,471,760.86. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Paul Thomas sold 10,000 shares of the firm’s stock in a transaction on Tuesday, August 15th. The shares were sold at an average price of $154.71, for a total value of $1,547,100.00. Following the completion of the transaction, the director now owns 12,172 shares in the company, valued at approximately $1,883,130.12. The disclosure for this sale can be found here. Company insiders own 7.00% of the company’s stock.

A number of hedge funds and other institutional investors have recently made changes to their positions in ABMD. BlackRock Inc. raised its position in shares of ABIOMED by 3.2% in the second quarter. BlackRock Inc. now owns 3,373,655 shares of the medical equipment provider’s stock worth $483,444,000 after buying an additional 103,410 shares during the last quarter. Vanguard Group Inc. raised its position in shares of ABIOMED by 1.6% in the second quarter. Vanguard Group Inc. now owns 3,317,593 shares of the medical equipment provider’s stock worth $475,411,000 after buying an additional 51,055 shares during the last quarter. Baillie Gifford & Co. raised its position in shares of ABIOMED by 17.9% in the second quarter. Baillie Gifford & Co. now owns 1,971,690 shares of the medical equipment provider’s stock worth $282,543,000 after buying an additional 299,255 shares during the last quarter. Palo Alto Investors LLC raised its position in shares of ABIOMED by 1.6% in the second quarter. Palo Alto Investors LLC now owns 1,951,284 shares of the medical equipment provider’s stock worth $279,619,000 after buying an additional 29,800 shares during the last quarter. Finally, William Blair Investment Management LLC raised its position in shares of ABIOMED by 8.9% in the first quarter. William Blair Investment Management LLC now owns 1,121,017 shares of the medical equipment provider’s stock worth $140,351,000 after buying an additional 91,651 shares during the last quarter. Institutional investors own 91.09% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece on another domain, it was stolen and reposted in violation of international trademark & copyright laws. The correct version of this piece can be viewed at https://www.thecerbatgem.com/2017/08/21/abiomed-inc-abmd-receives-157-50-consensus-target-price-from-analysts.html.

Shares of ABIOMED (ABMD) traded up 0.86% during trading on Friday, hitting $153.45. 145,878 shares of the stock traded hands. ABIOMED has a 12 month low of $95.14 and a 12 month high of $157.41. The company has a 50 day moving average price of $147.23 and a 200 day moving average price of $132.32. The firm has a market cap of $6.74 billion, a price-to-earnings ratio of 89.74 and a beta of 0.20.

ABIOMED (NASDAQ:ABMD) last issued its quarterly earnings data on Thursday, July 27th. The medical equipment provider reported $0.45 EPS for the quarter, topping analysts’ consensus estimates of $0.42 by $0.03. The business had revenue of $132.47 million for the quarter, compared to analysts’ expectations of $130.83 million. ABIOMED had a net margin of 16.13% and a return on equity of 13.03%. The business’s revenue was up 28.6% on a year-over-year basis. During the same quarter last year, the company earned $0.29 EPS. Analysts anticipate that ABIOMED will post $2.24 earnings per share for the current fiscal year.

About ABIOMED

ABIOMED, Inc is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart.

Analyst Recommendations for ABIOMED (NASDAQ:ABMD)

Receive News & Stock Ratings for ABIOMED Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED Inc. and related stocks with our FREE daily email newsletter.